Early brain injury Tropomyosin-related kinase receptor B Apoptosis N-acetyl serotonin derivative Brain-derived neurotrophic factor N-[2-(5-hydroxy-1H-indol-3-yl) ethyl]-2-oxopiperidine-3-carboxamide (HIOC), an N-acetyl serotonin derivative, selectively activates tropomyosin-related kinase receptor B (TrkB). This study is to investigate a potential role of HIOC on ameliorating early brain injury after experimental subarachnoid hemorrhage (SAH). One hundred and fifty-six adult male Sprague-Dawley rats were used. SAH model was induced by endovascular perforation. TrkB small interfering RNA (siRNA) or scramble siRNA was injected intracerebroventricularly 24 h before SAH. HIOC was administrated intracerebroventricularly 3 h after SAH and compared with brain-derived neurotrophic factor (BDNF). SAH grade and neurologic scores were evaluated for the outcome study. For the mechanism study, the expression of TrkB, phosphorylated TrkB (p-TrkB), phosphorylated extracellular signal regulated kinase (p-ERK), B-cell lymphoma 2 (Bcl-2) and cleaved caspase 3 (CC3) was detected by Western blots, and neuronal injury was determined by double immunofluorescence staining of neuronal nuclei and terminal deoxynucleotidyl transferase-mediated uridine 5′-triphosphate-biotin nick end-labeling. Knocking down of TrkB decreased the expression of Bcl-2 and aggravated neurologic deficits 24 h after SAH. HIOC activated TrkB/ ERK pathway, decreased neuronal cell death, and improved neurobehavioral outcome, and these effects were abolished by TrkB siRNA. HIOC was more potent than BDNF in reduction of apoptosis 24 h post-SAH. Thus, we conclude that administration of HIOC activated TrkB/ERK signaling cascade and attenuated early brain injury after SAH. HIOC may be a promising agent for further treatment for SAH and other stroke events.
Introduction
Subarachnoid hemorrhage (SAH) accounts for only 5% of all stroke incidents. However, due to its high rate of death and complications, the management of SAH remains to be one of the toughest challenges faced by physicians (Suarez et al., 2006; van Gijn et al., 2007) . The importance of early brain injury after SAH has been emphasized in the last decade as a key issue that may affect the prognosis of SAH (Caner et al., 2012; Chen et al., 2014; Kusaka et al., 2004; Sehba et al., 2012) .
Recent studies have shown that anti-apoptosis may attenuate early brain injury after experimental SAH (Hasegawa et al., 2011b) .
Tropomyosin-related kinase receptor B (TrkB) belongs to the receptor tyrosine kinase (RTK) family (Boulle et al., 2012) . Phosphorylation of TrkB ameliorated brain injury in ischemic stroke models (Cui et al., 2013; Van Kanegan et al., 2014) . Our previous study revealed that the brain-derived neurotrophic factor (BDNF)/TrkB signaling pathway was involved in apoptosis after SAH (Hasegawa et al., 2011a) . N-acetyl serotonin (NAS), which is an intermediate in the endogenous synthesis of melatonin from serotonin, has been demonstrated to activate TrkB receptor and exert anti-depressant effects in a TrkB-dependent manner (Jang et al., 2010) . N-[2-(5-hydroxy-1H-indol-3-yl) ethyl]-2-oxopiperidine-3-carboxamide (HIOC) is one of the derivatives of NAS. It selectively activates TrkB receptor with greater potency than NAS (Shen et al., 2012) . However, the role of HIOC in stroke models has not been evaluated.
In the present study, we hypothesized that administration of HIOC would activate TrkB and its downstream effector extracellular signal 
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